EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Association and Predictive Value of Nutritional and Inflammatory Biomarkers in Advanced Non-Small Cell Lung Cancer Response to Immune Checkpoint Inhibitors

Mirte Dekker iD, Erick Suazo-Zepeda iD, T Jeroen N Hiltermann iD, Geertruida H De Bock iD, Marjolein A Heuvelmans

Cancers · 08.07.2026 · 18 (14) · 2185

DOI: 10.3390/cancers18142185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 08.07.2026. Verfasst von Mirte Dekker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mexico's National Council of Science and Technology (CONACYT), European Union, Mexico’s National Council of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Immune checkpoint inhibitors (ICIs) have broadened treatment options for non-small cell lung cancer (NSCLC), but many patients show limited response. Baseline biomarkers and indices, including C-reactive protein (CRP), albumin, Neutrophil-to-Lymphocyte Ratio (NLR), Glasgow Prognostic Score (GPS), Prognostic Nutrition Index (PNI), and Advanced Lung Cancer Inflammation Index (ALI), may predict treatment outcomes. This study evaluated whether these biomarkers associate with three-month mortality and disease progression assessed by disease control rate (DCR) using RECIST.

Methods

We conducted a retrospective cohort study of consecutive patients with NSCLC from the OncoLifeS biobank (2015–2020). Three-month mortality was defined by status alive or deceased at three months after treatment start. DCR was based on CT-assessments using RECIST. Univariate and multivariable logistic regression models with backward selection and bootstrapping were developed to test biomarker associations with three-month mortality and DCR. Sensitivity analysis was performed to compare results with the standard definition of objective response rate (ORR).

Results

Among 505 patients, 421 were alive and 84 deceased; 297 were responders and 208 non-responders. In the final progression model, higher GPS was associated with increased odds of 3-month progression, whereas higher ALI (OR 0.99, 95% CI 0.97–1.00) and higher PNI (OR 0.93, 95% CI 0.87–0.99) were associated with decreased odds of 3-month progression. Higher ALI (OR 0.97, 95% CI 0.94–0.99), and higher PNI (OR 0.83, 95% CI 0.78–0.89) were associated with lower odds of 3-month mortality. The mortality-model showed an AUC of 0.82 and 0.73 for the disease progression model. Sensitivity analysis with the standard RECIST definition revealed similar results.

Conclusions

Higher GPS was associated with increased risk of progression, whereas higher PNI and ALI were associated with lower risk of progression and mortality. These findings warrant external validation before clinical implementation.

Schlagwörter

Stichwörter der Autor:innen

biomarkerscarcinomadisease progressionimmune checkpoint inhibitorsnon-small cell lung

Autor:innen und Institutionen

  • Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Department of Pulmonary, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Institute for Diagnostic Accuracy, 9713 GH Groningen, The Netherlands.
  • Department of Respiratory Medicine, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.

ORCID-Profile: Mirte Dekker, Erick Suazo-Zepeda, T Jeroen N Hiltermann, Geertruida H De Bock

Förderung

  • Mexico's National Council of Science and Technology (CONACYT)
  • European Union
  • Mexico’s National Council of Science and Technology
  • European Union’s Horizon 2020 research and innovation program

Zitieren

APA

Dekker, M., Suazo-Zepeda, E., Hiltermann, T. J. N., De Bock, G. H., & Heuvelmans, M. A. (2026). The Association and Predictive Value of Nutritional and Inflammatory Biomarkers in Advanced Non-Small Cell Lung Cancer Response to Immune Checkpoint Inhibitors. Cancers, 18(14), 2185. https://doi.org/10.3390/cancers18142185

Vancouver

Dekker M, Suazo-Zepeda E, Hiltermann TJN, De Bock GH, Heuvelmans MA. The Association and Predictive Value of Nutritional and Inflammatory Biomarkers in Advanced Non-Small Cell Lung Cancer Response to Immune Checkpoint Inhibitors. Cancers. 2026;18(14):2185. doi:10.3390/cancers18142185

BibTeX
@article{Dekker2026,
  author = {Dekker, Mirte and Suazo-Zepeda, Erick and Hiltermann, T Jeroen N and De Bock, Geertruida H and Heuvelmans, Marjolein A},
  title = {The Association and Predictive Value of Nutritional and Inflammatory Biomarkers in Advanced Non-Small Cell Lung Cancer Response to Immune Checkpoint Inhibitors},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {14},
  pages = {2185},
  doi = {10.3390/cancers18142185}
}
Kostenlos starten →